| Biomarker ID | 442 |
| PMID | 19351846 |
| Year | 2009 |
| Biomarker | ACPP; AD-017; AMIGO2; APPBP2; ASNS; ATAD2; ATP6V0E; ATXN1; AURKB; B3GALT4; BANK1; BCAP29; BIRC5; BM039 (CENPN); BRE; BUB1; BUB1B; C18orf10; C1orf9; C22orf18 (CENPM); C5orf13; C6orf111; C6orf210; C9orf116; C9orf127; CATSPER2; CCNA2; CCNB1; CCNB2; CCNE2; CD24; CDC16; CDC2; CDC20; CDC25C; CDC6; CDC7; CDKN3; CENPA; CENPC1; CENPF; CHEK1; CHEK1; CITED2; CITED2; CLUL1; COH1; CPT2; CRADD; CTSL2; CYFIP2; DEPDC1; DGKA; DMXL1; DSCR1L1; EFNB2; ESPL1; F2R; FEN1; FLJ10036; FLJ10534; FLJ22624; GABARAPL1; GALNT7; GFPT1; GGA2; GTSE1; GTSE1; H2AFX; H2AFY; HCAP-G; HCAP-G; HECA; HMGB2; HMMR; HMMR; HPS1; IL13RA1; INSIG1; KIAA0999; KIAA1608; KIF14; KIF20A; KIF4A KLK2; KLK2; KLK3; KNS2; KNTC2; LAMB2; LMAN1; LOC54103; MAC30; MALT1; MAPK8IP1; MCM5 ; MID1; MLF1IP; MLLT3; MTHFD2; MTMR1; MYCBP2; MYH10; MYRIP; NAP1L3; NAV3; NEK2; NEK2 NLGN1; NUSAP1; OIP5; OSR2; PBEF1; PCLO; PDE9A; PDIR; PER3; PIK3R1;PINK1; PIR51; PLCB4; PLK1; PMAIP1; PMS2L11; PMSCL1; PRC1; PRKWNK1; PTBP1; PTBP2; PTCD1 ; PTPN13; PTPRR; RAB3B; RACGAP1; RBM30; RFC3; RRM1 ; RRM2; RRM2; SAS; SDC2 ; SDC2 ; SDC4; SEC6L1; SHCBP1 ; SI; SLC29A1; SLC7A6; SMARCA2; SMC4L1; SMC4L1; SOCS2; SOD2; SOS1; Spc25; SS18; STC2; STK3; STK6 ; TM4SF1; TMPO; TNFRSF10B ; TNFSF13; TNFSF12-TNFSF13; TWE-PRIL; TOPK; TPBG; TPX2; TRIB1; TTC3; TUBA3; TYMS; UAP1; UBE3B; USP3; VEGF; ZNF175; ZNF292; ZNF45; ZWINT |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Metastatic Vs Localised Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Training: benign (n = 6), localized (n = 7), and metastasic (n = 6) prostate cancer patients were included for this analysis. Testing: 18 benign prostate tissues, 63 subbenign samples from the tissues beside the primary tumor, 61 primary PCa, and 25 samples of metastatic PCa were included. (PubMed GEO (GDS1439, GSE6919, and GDS1390)) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | Training: 100%; Testing: 89% |
| Level Of Significance | p=0.0000121714 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent patient dataset |
| Technical Name | ACPP, AD-017, AMIGO2, APPBP2, ASNS, ATAD2, ATP6V0E, ATXN1, AURKB, B3GALT4, BANK1, BCAP29, BIRC5, BM039 (CENPN), BRE, BUB1, BUB1B, C18orf10, C1orf9, C22orf18 (CENPM), C5orf13, C6orf111, C6orf210, C9orf116, C9orf127, CATSPER2, CCNA2, CCNB1, CCNB2, CCNE2, CD24, CDC16, CDC2, CDC20, CDC25C, CDC6, CDC7, CDKN3, CENPA, CENPC1, CENPF, CHEK1, CHEK1, CITED2, CITED2, CLUL1, COH1, CPT2, CRADD, CTSL2, CYFIP2, DEPDC1, DGKA, DMXL1, DSCR1L1, EFNB2, ESPL1, F2R, FEN1, FLJ10036, FLJ10534, FLJ22624, GABARAPL1, GALNT7, GFPT1, GGA2, GTSE1, GTSE1, H2AFX, H2AFY, HCAP-G, HCAP-G, HECA, HMGB2, HMMR, HMMR, HPS1, IL13RA1, INSIG1, KIAA0999, KIAA1608, KIF14, KIF20A, KIF4A KLK2, KLK2, KLK3, KNS2, KNTC2, LAMB2, LMAN1, LOC54103, MAC30, MALT1, MAPK8IP1, MCM5, MID1, MLF1IP, MLLT3, MTHFD2, MTMR1, MYCBP2, MYH10, MYRIP, NAP1L3, NAV3, NEK2, NEK2 NLGN1, NUSAP1, OIP5, OSR2, PBEF1, PCLO, PDE9A, PDIR, PER3, PIK3R1, PINK1, PIR51, PLCB4, PLK1, PMAIP1, PMS2L11, PMSCL1, PRC1, PRKWNK1, PTBP1, PTBP2, PTCD1, PTPN13, PTPRR, RAB3B, RACGAP1, RBM30, RFC3, RRM1, RRM2, RRM2, SAS, SDC2, SDC2, SDC4, SEC6L1, SHCBP1, SI, SLC29A1, SLC7A6, SMARCA2, SMC4L1, SMC4L1, SOCS2, SOD2, SOS1, Spc25, SS18, STC2, STK3, STK6, TM4SF1, TMPO, TNFRSF10B, TNFSF13, TNFSF12-TNFSF13, TWE-PRIL, TOPK, TPBG, TPX2, TRIB1, TTC3, TUBA3, TYMS, UAP1, UBE3B, USP3, VEGF, ZNF175, ZNF292, ZNF45, ZWINT |